AVA-011 / Avalon GloboCare, Arbele - LARVOL DELTA

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors (clinicaltrials.gov) - P1 | N=100 | Recruiting | Sponsor: Hebei Senlang Biotechnology Inc., Ltd.

CAR T-Cell Therapy • New P1 trial • Hematological Disorders • Hematological Malignancies • Oncology • CD19 • CD22

Avalon GloboCare Expands its Cellular Immuno-Oncology Platform with the Addition of Novel Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cell Therapies (GlobeNewswire) - "Avalon GloboCare Corp...announced today that the Company is expanding its cellular immuno-oncology program with the addition of novel Chimeric Antigen Receptor – Natural Killer (CAR-NK) cell therapies....Avalon plans to expand its clinical program in collaboration with its major clinical trial partner, the Lu Daopei Hospital....The new CAR-NK therapies in development are intended to build upon and complement AVA-011, Avalon’s lead CAR-T candidate, part of the Company’s proprietary mRNA-based FLASH-CAR™ platform."

Clinical • Licensing / partnership • Hematological Malignancies • Oncology

Avalon GloboCare Announces Collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center to Advance Clinical Development of Cellular Immunotherapies Using the FLASH-CAR Platform (Avalon GloboCare Corp Press Release) - "Avalon GloboCare...today announces entering into a collaboration agreement with the University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center to advance the clinical development and production of Avalon’s next-generation, chimeric antigen receptor (CAR) therapies using FLASH CAR™ technology...Avalon’s first FLASH-CAR™ platform candidate, AVA-011, targets both CD19 and CD22 tumor antigens on cancer cells and is in development for patients with relapsed/refractory B-cell lymphoblastic leukemia and non-Hodgkin’s lymphoma....'This is an important milestone in the clinical development and production of AVA-011 and other RNA-based FLASH-CAR™ candidates ahead of the start of our first-in-human clinical trials,'..."

Licensing / partnership • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology